Background Psoriasis is an immune‐mediated disease with either skin or joints
manifestations, or both, and it has a major impact on quality of life. Although there is …

Introduction New generation biologics, including interleukin (IL)-17 and IL-23 inhibitors,
have delivered higher rates of skin clearance than older treatments in head-to-head studies …

Pulmonary fibrosis is a progressive inflammatory disease with high mortality and limited
therapeutic options. Previous genetic and immunologic investigations suggest common …

Objective: To systematically analyze the efficacy and safety of interleukin (IL)-12/23, IL-17,
and selective IL-23 inhibitors in moderate to severe plaque psoriasis. Methods and results …

γδ T lymphocytes maintain skin homeostasis by balancing keratinocyte differentiation and
proliferation with the destruction of infected or malignant cells. An imbalance in skin-resident …

Multiple biologic treatments are licensed for psoriasis. The lack of head-to-head randomized
controlled trials makes choosing between them difficult for patients, clinicians, and guideline …

Background The rapid expansion of psoriasis biologics has led to an urgent need to
understand their relative efficacy and tolerability to inform treatment decisions better and …

Background Comorbidities of cardiovascular diseases (CVDs), metabolic syndrome and
autoimmune diseases with systemic inflammation are recent topics in medicine …

Psoriasis and atopic dermatitis are common, chronic inflammatory skin diseases. We
discuss several aspects of these disorders, including: risk factors; incidence and prevalence; …

Background Registry studies broadly describing the safety of systemic drugs in psoriasis are
needed. Objective To describe the safety findings of the systemic drugs acitretin …